CARDIOLOGY

Identifying Subclinical Transthyretin Cardiac Amyloidosis in V142I TTR Carriers: Design, Rationale, and Methods of the VISTA (Variant Imaging of Subclinical Transthyretin Amyloidosis) Study

Aug 8, 2026 by in CARDIOLOGY Comments Off on Identifying Subclinical Transthyretin Cardiac Amyloidosis in V142I TTR Carriers: Design, Rationale, and Methods of the VISTA (Variant Imaging of Subclinical Transthyretin Amyloidosis) Study
Background Approximately 1.5 million of the 44 million individuals of African descent in the United States are carriers of the p.V142I variant in transthyretin (TTR). This is the most common…
read more

Serial Assessment of Vascular Healing Process After Directional Coronary Atherectomy Followed by Drug-Coated Balloon: An Optical Coherence Tomography Study

Aug 8, 2026 by in CARDIOLOGY Comments Off on Serial Assessment of Vascular Healing Process After Directional Coronary Atherectomy Followed by Drug-Coated Balloon: An Optical Coherence Tomography Study
Highlights • Luminal narrowing occurs during the first 6 months after DCA and DCB. • Main mechanism of luminal narrowing after DCA and DCB is layer progression. • DM and…
read more

Effectiveness and Safety of Apixaban Versus Warfarin in Atrial Fibrillation Patients With Malignancy: A Propensity-Matched Analysis

Aug 8, 2026 by in CARDIOLOGY Comments Off on Effectiveness and Safety of Apixaban Versus Warfarin in Atrial Fibrillation Patients With Malignancy: A Propensity-Matched Analysis
Patients with atrial fibrillation and malignancy have increased risks of thromboembolism and bleeding. Evidence comparing apixaban and warfarin in this group remains limited. We aimed to compare effectiveness and safety…
read more

Impact of Comprehensive STEMI Protocol on Process Metrics and Clinical Outcomes in STEMI Patients With Nonsystem Delays

Aug 8, 2026 by in CARDIOLOGY Comments Off on Impact of Comprehensive STEMI Protocol on Process Metrics and Clinical Outcomes in STEMI Patients With Nonsystem Delays
Highlights • 4-step STEMI protocol improved care in patients with nonsystem delays. • Protocol reduced door-to-balloon time from 132 to 101 minutes. • Rates of bleeding, shock, and AKI significantly…
read more

SCAD and Atypical Chest Pain: A Simple Check, or a Trap?

Aug 8, 2026 by in CARDIOLOGY Comments Off on SCAD and Atypical Chest Pain: A Simple Check, or a Trap?
A 47-year-old woman with a history of multiple previous spontaneous coronary artery dissection (SCAD) episodes, treated both conservatively and with percutaneous coronary intervention (PCI), was referred for coronary angiography due…
read more

Erratum to ‘Trends, Predictors, and Outcomes of Temporary Mechanical Circulatory Support for Postcardiac Surgery Cardiogenic Shock’ [The American Journal of Cardiology 123(2019) Pages 489-497]

Aug 8, 2026 by in CARDIOLOGY Comments Off on Erratum to ‘Trends, Predictors, and Outcomes of Temporary Mechanical Circulatory Support for Postcardiac Surgery Cardiogenic Shock’ [The American Journal of Cardiology 123(2019) Pages 489-497]
The Publisher regrets that, in the originally published version of this article, Figures 2 and 5 were transposed; the captions were correct as numbered. The article has been updated so…
read more

Clinical Approaches in Heart Failure: Perspectives of Cardiologists in Türkiye (HF-PERSPECTIVE)

Aug 8, 2026 by in CARDIOLOGY Comments Off on Clinical Approaches in Heart Failure: Perspectives of Cardiologists in Türkiye (HF-PERSPECTIVE)
Guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) is centered on 4 foundational drug classes: renin–angiotensin system inhibition (ACE inhibitor/ARB or angiotensin receptor–neprilysin inhibitor [ARNI]), evidence-based…
read more

Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials

Aug 8, 2026 by in CARDIOLOGY Comments Off on Mavacamten and Aficamten in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Trials
Myosin inhibitors represent a novel therapeutic class for hypertrophic cardiomyopathy (HCM). While both mavacamten and aficamten have been evaluated in randomized trials, comparative evidence across the 2 agents remains limited….
read more

Impact of Frailty on Outcomes Following Percutaneous Left Atrial Appendage Occlusion: A Propensity-Score Matched Analysis

Aug 8, 2026 by in CARDIOLOGY Comments Off on Impact of Frailty on Outcomes Following Percutaneous Left Atrial Appendage Occlusion: A Propensity-Score Matched Analysis
Brief Report Atrial fibrillation (AF) increases the risk of embolic stroke by fivefold in high-risk patients. Percutaneous left atrial appendage occlusion (LAAO) has emerged as an established alternative for those…
read more
Get Clinical Tree app for offline access